Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 10
Encontrada(s) 1 página(s)

Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Precision medicine based in epigenomics: the paradigm of carcinoma of unknown primary

  • Moran, Sebastian
  • Martínez Cardús, Anna
  • Boussios, S.
  • Esteller, Manel, 1968-
Epigenetic alterations are a common hallmark of human cancer. Single epigenetic markers are starting to be incorporated into clinical practice; however, the translational use of these biomarkers has not been validated at the 'omics' level. The identification of the tissue of origin in patients with cancer of unknown primary (CUP) is an example of how epigenomics can be incorporated in clinical settings, addressing an unmet need in the diagnostic and clinical management of these patients. Despite the great diagnostic advances made in the past decade, the use of traditional diagnostic procedures only enables the tissue of origin to be determined in ∼30% of patients with CUP. Thus, development of molecularly guided diagnostic strategies has emerged to complement traditional procedures, thereby improving the clinical management of patients with CUP. In this Review, we present the latest data on strategies using epigenetics and other molecular biomarkers to guide therapeutic decisions involving patients with CUP, and we highlight areas warranting further research to engage the medical community in this unmet need.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Circular RNA CpG island hypermethylation-associated silencing in human cancer

  • Ferreira, Humberto J.
  • Davalos, Veronica
  • Castro de Moura, Manuel
  • Soler, Marta
  • Pérez Salvia, Montserrat
  • Bueno Costa, Alberto
  • Setién, Fernando
  • Moran, Sebastian
  • Villanueva Garatachea, Alberto
  • Esteller, Manel, 1968-
Noncoding RNAs (ncRNAs), such as microRNAs and long noncoding RNAs (lncRNAs), participate in cellular transformation. Work done in the last decade has also demonstrated that ncRNAs with growth-inhibitory functions can undergo promoter CpG island hypermethylation-associated silencing in tumorigenesis. Herein, we wondered whether circular RNAs (circRNAs), a type of RNA transcripts lacking 5′-3′ ends and forming closed loops that are gaining relevance in cancer biology, are also a target of epigenetic inactivation in tumors. To tackle this issue, we have used cancer cells genetically deficient for the DNA methyltransferase enzymes in conjuction with circRNA expression microarrays. We have found that the loss of DNA methylation provokes a release of circRNA silencing. In particular, we have identified that promoter CpG island hypermethylation of the genes TUSC3 (tumor suppressor candidate 3), POMT1 (protein O-mannosyltransferase 1), ATRNL1 (attractin-like 1) and SAMD4A (sterile alpha motif domain containing 4A) is linked to the transcriptional downregulation of both linear mRNA and the hosted circRNA. Although some circRNAs regulate the linear transcript, we did not observe changes in TUSC3 mRNA levels upon TUSC3 circ104557 overexpression. Interestingly, we found circRNA-mediated regulation of target miRNAs and an in vivo growth inhibitory effect upon TUSC3 circ104557 transduction. Data mining for 5′-end CpG island methylation of TUSC3, ATRNL1, POMT1 and SAMD4A in cancer cell lines and primary tumors showed that the epigenetic defect was commonly observed among different tumor types in association with the diminished expression of the corresponding transcript. Our findings support a role for circRNA DNA methylation-associated loss in human cancer.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

MeCP2-E1 isoform is a dynamically expressed, weakly DNA-bound protein with different protein and DNA interactions compared to MeCP2-E2

  • Martínez de Paz, Alexia
  • Khajavi, Leila
  • Martin, Hélène
  • Clavería Gimeno, Rafael
  • Dieck, Susanne Tom
  • Cheema, Manjinder
  • Sanchez-Mut, Jose Vicente
  • Moksa, Malgorzata M.
  • Carles, Annaick
  • Brodie, Nick I.
  • Sheikh, Taimoor I.
  • Freeman, Melissa E.
  • Petrotchenko, Evgeniy V.
  • Borchers, Christoph H.
  • Schuman, Erin M.
  • Zytnicki, Matthias
  • Velazquez-Campoy, Adrian
  • Abian, Olga
  • Hirst, Martin
  • Esteller, Manel, 1968-
  • Vincent, John B.
  • Malnou, Cécile E.
  • Ausió, Juan
Background: MeCP2-a chromatin-binding protein associated with Rett syndrome-has two main isoforms, MeCP2-E1 and MeCP2-E2, differing in a few N-terminal amino acid residues. Previous studies have shown brain region-specific expression of these isoforms which, in addition to their different cellular localization and differential expression during brain development, suggest that they may also have non-overlapping molecular mechanisms. However, differential functions of MeCP2-E1 and E2 remain largely unexplored. Results: here, we show that the N-terminal domains (NTD) of MeCP2-E1 and E2 modulate the ability of the methyl-binding domain (MBD) to interact with DNA as well as influencing the turn-over rates, binding dynamics, response to neuronal depolarization, and circadian oscillations of the two isoforms. Our proteomics data indicate that both isoforms exhibit unique interacting protein partners. Moreover, genome-wide analysis using ChIP-seq provide evidence for a shared as well as a specific regulation of different sets of genes. Conclusions: our study supports the idea that Rett syndrome might arise from simultaneous impairment of cellular processes involving non-overlapping functions of MECP2 isoforms. For instance, MeCP2-E1 mutations might impact stimuli-dependent chromatin regulation, while MeCP2-E2 mutations could result in aberrant ribosomal expression. Overall, our findings provide insight into the functional complexity of MeCP2 by dissecting differential aspects of its two isoforms.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicenter, retrospective analysis

  • Duruisseaux, Michäel
  • Martínez Cardús, Anna
  • Calleja Cervantes, Maria E.
  • Moran, Sebastian
  • Castro de Moura, Manuel
  • Davalos, Veronica
  • Piñeyro, David
  • Sánchez Céspedes, Montserrat
  • Girard, Nicolas
  • Brevet, Marie
  • Giroux-Leprieur, Etienne
  • Dumenil, Coraline
  • Pradotto, Monica
  • Bironzo, Paolo
  • Capelletto, Enrica
  • Novello, Silvia
  • Cortot, Alexis
  • Copin, Marie-Christine
  • Karachaliou, Niki
  • Gonzalez Cao, Maria
  • Ruffinelli, Sergio
  • Palmero, Ramón
  • Nadal, Ernest
  • Moran, Teresa
  • Perez, Lidia
  • Ramos, Immaculada
  • Xiao, Qingyang
  • Fernández, Agustín F.
  • Fraga, Mario F.
  • Gut, Marta
  • Gut, Ivo G.
  • Teixidó Febrero, Cristina
  • Vilariño, Noelia
  • Prat Aparicio, Aleix
  • Reguart, Noemí
  • Benito, Amparo
  • Garrido, Pilar
  • Barragan, Isabel
  • Emile, Jean-François
  • Rosell Costa, R.
  • Brambilla, Elisabeth
  • Esteller, Manel, 1968-
Background: Anti-programmed death-1 (PD-1) treatment for advanced non-small-cell lung cancer (NSCLC) has improved the survival of patients. However, a substantial percentage of patients do not respond to this treatment. We examined the use of DNA methylation profiles to determine the efficacy of anti-PD-1 treatment in patients recruited with current stage IV NSCLC. Methods: In this multicentre study, we recruited adult patients from 15 hospitals in France, Spain, and Italy who had histologically proven stage IV NSCLC and had been exposed to PD-1 blockade during the course of the disease. The study structure comprised a discovery cohort to assess the correlation between epigenetic features and clinical benefit with PD-1 blockade and two validation cohorts to assess the validity of our assumptions. We first established an epigenomic profile based on a microarray DNA methylation signature (EPIMMUNE) in a discovery set of tumour samples from patients treated with nivolumab or pembrolizumab. The EPIMMUNE signature was validated in an independent set of patients. A derived DNA methylation marker was validated by a single-methylation assay in a validation cohort of patients. The main study outcomes were progression-free survival and overall survival. We used the Kaplan-Meier method to estimate progression-free and overall survival, and calculated the differences between the groups with the log-rank test. We constructed a multivariate Cox model to identify the variables independently associated with progression-free and overall survival. Findings: Between June 23, 2014, and May 18, 2017, we obtained samples from 142 patients: 34 in the discovery cohort, 47 in the EPIMMUNE validation cohort, and 61 in the derived methylation marker cohort (the T-cell differentiation factor forkhead box P1 [FOXP1]). The EPIMMUNE signature in patients with stage IV NSCLC treated with anti-PD-1 agents was associated with improved progression-free survival (hazard ratio [HR] 0·010, 95% CI 3·29 × 10 −4–0·0282; p=0·0067) and overall survival (0·080, 0·017–0·373; p=0·0012). The EPIMMUNE-positive signature was not associated with PD-L1 expression, the presence of CD8+ cells, or mutational load. EPIMMUNE-negative tumours were enriched in tumour-associated macrophages and neutrophils, cancer-associated fibroblasts, and senescent endothelial cells. The EPIMMUNE-positive signature was associated with improved progression-free survival in the EPIMMUNE validation cohort (0·330, 0·149–0·727; p=0·0064). The unmethylated status of FOXP1 was associated with improved progression-free survival (0·415, 0·209–0·802; p=0·0063) and overall survival (0·409, 0·220–0·780; p=0·0094) in the FOXP1 validation cohort. The EPIMMUNE signature and unmethylated FOXP1 were not associated with clinical benefit in lung tumours that did not receive immunotherapy. Interpretation: Our study shows that the epigenetic milieu of NSCLC tumours indicates which patients are most likely to benefit from nivolumab or pembrolizumab treatments. The methylation status of FOXP1 could be associated with validated predictive biomarkers such as PD-L1 staining and mutational load to better select patients who will experience clinical benefit with PD-1 blockade, and its predictive value should be evaluated in prospective studies.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

MeCP2-E1 isoform is a dynamically expressed, weakly DNA-bound protein with diferent protein and DNA interactions compared to MeCP2-E2

  • Martínez de Paz, Alexia
  • Khajavi, Leila
  • Martin, Hélène
  • Claveria-Gimeno, Rafael
  • Dieck, S. T.
  • Cheema, Manjinder S.
  • Sánchez-Mut, José V.
  • Moksa, Malgorzata M.
  • Carles, Annaick
  • Brodie, Nick I.
  • Sheikh, Taimoor I.
  • Freenan, Melissa E.
  • Petrotchenko, Evgeniy V.
  • Borchers, Christoph H.
  • Schuman, Erin M.
  • Zytnicki, Matthias
  • Velázquez-Campoy, Adrián
  • Abian, Olga
  • Hirst, Martin
  • Estelller, Manel
  • Vincent, John B.
  • Malnou, Cécile E.
  • Ausió, Juan
16 pags., 5 figs.-- Open Access funded by Creative Commons Atribution Licence 4.0, BACKGROUND: MeCP2-a chromatin-binding protein associated with Rett syndrome-has two main isoforms, MeCP2-E1 and MeCP2-E2, differing in a few N-terminal amino acid residues. Previous studies have shown brain region-specific expression of these isoforms which, in addition to their different cellular localization and differential expression during brain development, suggest that they may also have non-overlapping molecular mechanisms. However, differential functions of MeCP2-E1 and E2 remain largely unexplored. RESULTS: Here, we show that the N-terminal domains (NTD) of MeCP2-E1 and E2 modulate the ability of the methyl-binding domain (MBD) to interact with DNA as well as influencing the turn-over rates, binding dynamics, response to neuronal depolarization, and circadian oscillations of the two isoforms. Our proteomics data indicate that both isoforms exhibit unique interacting protein partners. Moreover, genome-wide analysis using ChIP-seq provide evidence for a shared as well as a specific regulation of different sets of genes. CONCLUSIONS: Our study supports the idea that Rett syndrome might arise from simultaneous impairment of cellular processes involving non-overlapping functions of MECP2 isoforms. For instance, MeCP2-E1 mutations might impact stimuli-dependent chromatin regulation, while MeCP2-E2 mutations could result in aberrant ribosomal expression. Overall, our findings provide insight into the functional complexity of MeCP2 by dissecting differential aspects of its two isoforms., This work was supported by the Canadian Institutes of Health Research [MOP-130417 to JA and MOP-102758 to JBV]. Genome Canada and Genome British Columbia for fnancial support for the University of Victoria-Genome BC Proteomics Centre [204PRO and 214PRO], Leading Edge Endowment Fund (University of Victoria), the Segal McGill Chair in Molecular Oncology at McGill University, the Warren Y. Soper Charitable Trust and the Alvin Segal Family Foundation to the Jewish General Hospital to CHB. Max Planck Society and DFG CRC 1080; DFG CRC 902 to EMS. European Research Council under the European Union’s Horizon 2020 research and innovation program [743216 to EMS and 727264 (EPIPHARM) to ME]. Spanish Ministerio de Economia y Competitividad [BFU2013-47064-P and BFU2016-78232-P to AVC and SAF201455000-R to ME]. Instituto de Salud Carlos III and co-funded by European Union (ERDF/ESF, “Investing in your future”) [PI15/00663, and Miguel Servet contract CPII13/0017] to OA. Spanish Ministerio de Educacion Cultura y Deporte [FPU 13/3870] to RCG. Terry Fox Research Institute Program Project [TFRI #1039] and Canadian Cancer Society Research Institute [CCSRI #703489] to MH. European Community’s Seventh Framework Programme (FP7/2007–2013)/ERC [268626/ EPINORC project]; Integrated Project of Excellence [PIE13/00022] (ONCOPRO‑FILE); CIBER 2016 CB16/12/00312 (CIBERONC); the Spanish Cancer Research Network [RD12/0036/0039]; the Cellex Foundation; Obra Social “La Caixa”; and the Health and Science Departments of the Catalan Government (Generalitat de Catalunya) AGAUR [2014SGR633] to ME. ME is an ICREA Research Professor. French Association of Rett Syndrome funded research conducted by CEM, HM and LK, genotoul bioinformatics platform Toulouse Midi-Pyrenees (Bioinfo Genotoul) provided computing and storage resources., Peer reviewed
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

MeCP2-E1 isoform is a dynamically expressed, weakly DNA-bound protein with different protein and DNA interactions compared to MeCP2-E2

  • Martínez De Paz, A.
  • Khajavi, L.
  • Martin, H.
  • Claveria-Gimeno, R.
  • Tom Dieck, S.
  • Cheema, M.S.
  • Sanchez-Mut, J.V.
  • Moksa, M.M.
  • Carles, A.
  • Brodie, N.I.
  • Sheikh, T.I.
  • Freeman, M.E.
  • Petrotchenko, E.V.
  • Borchers, C.H.
  • Schuman, E.M.
  • Zytnicki, M.
  • Velazquez-Campoy, A.
  • Abian, O.
  • Hirst, M.
  • Esteller, M.
  • Vincent, J.B.
  • Malnou, C.E.
  • Ausió, J.
Background: MeCP2- A chromatin-binding protein associated with Rett syndrome-has two main isoforms, MeCP2-E1 and MeCP2-E2, differing in a few N-terminal amino acid residues. Previous studies have shown brain region-specific expression of these isoforms which, in addition to their different cellular localization and differential expression during brain development, suggest that they may also have non-overlapping molecular mechanisms. However, differential functions of MeCP2-E1 and E2 remain largely unexplored. Results: Here, we show that the N-terminal domains (NTD) of MeCP2-E1 and E2 modulate the ability of the methyl-binding domain (MBD) to interact with DNA as well as influencing the turn-over rates, binding dynamics, response to neuronal depolarization, and circadian oscillations of the two isoforms. Our proteomics data indicate that both isoforms exhibit unique interacting protein partners. Moreover, genome-wide analysis using ChIP-seq provide evidence for a shared as well as a specific regulation of different sets of genes. Conclusions: Our study supports the idea that Rett syndrome might arise from simultaneous impairment of cellular processes involving non-overlapping functions of MECP2 isoforms. For instance, MeCP2-E1 mutations might impact stimuli-dependent chromatin regulation, while MeCP2-E2 mutations could result in aberrant ribosomal expression. Overall, our findings provide insight into the functional complexity of MeCP2 by dissecting differential aspects of its two isoforms.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicenter, retrospective analysis

  • Duruisseaux, Michäel
  • Martínez Cardús, Anna
  • Calleja Cervantes, Maria E.
  • Moran, Sebastian
  • Castro de Moura, Manuel
  • Davalos, Veronica
  • Piñeyro, David
  • Sánchez Céspedes, Montserrat
  • Girard, Nicolas
  • Brevet, Marie
  • Giroux-Leprieur, Etienne
  • Dumenil, Coraline
  • Pradotto, Monica
  • Bironzo, Paolo
  • Capelletto, Enrica
  • Novello, Silvia
  • Cortot, Alexis
  • Copin, Marie-Christine
  • Karachaliou, Niki
  • Gonzalez Cao, Maria
  • Ruffinelli, Sergio
  • Palmero, Ramón
  • Nadal, Ernest
  • Moran, Teresa
  • Perez, Lidia
  • Ramos, Immaculada
  • Xiao, Qingyang
  • Fernández, Agustín F.
  • Fraga, Mario F.
  • Gut, Marta
  • Gut, Ivo G.
  • Teixidó Febrero, Cristina
  • Vilariño, Noelia
  • Prat Aparicio, Aleix
  • Reguart, Noemí
  • Benito, Amparo
  • Garrido, Pilar
  • Barragan, Isabel
  • Emile, Jean-François
  • Rosell Costa, R.
  • Brambilla, Elisabeth
  • Esteller, Manel
Background: Anti-programmed death-1 (PD-1) treatment for advanced non-small-cell lung cancer (NSCLC) has improved the survival of patients. However, a substantial percentage of patients do not respond to this treatment. We examined the use of DNA methylation profiles to determine the efficacy of anti-PD-1 treatment in patients recruited with current stage IV NSCLC. Methods: In this multicentre study, we recruited adult patients from 15 hospitals in France, Spain, and Italy who had histologically proven stage IV NSCLC and had been exposed to PD-1 blockade during the course of the disease. The study structure comprised a discovery cohort to assess the correlation between epigenetic features and clinical benefit with PD-1 blockade and two validation cohorts to assess the validity of our assumptions. We first established an epigenomic profile based on a microarray DNA methylation signature (EPIMMUNE) in a discovery set of tumour samples from patients treated with nivolumab or pembrolizumab. The EPIMMUNE signature was validated in an independent set of patients. A derived DNA methylation marker was validated by a single-methylation assay in a validation cohort of patients. The main study outcomes were progression-free survival and overall survival. We used the Kaplan-Meier method to estimate progression-free and overall survival, and calculated the differences between the groups with the log-rank test. We constructed a multivariate Cox model to identify the variables independently associated with progression-free and overall survival. Findings: Between June 23, 2014, and May 18, 2017, we obtained samples from 142 patients: 34 in the discovery cohort, 47 in the EPIMMUNE validation cohort, and 61 in the derived methylation marker cohort (the T-cell differentiation factor forkhead box P1 [FOXP1]). The EPIMMUNE signature in patients with stage IV NSCLC treated with anti-PD-1 agents was associated with improved progression-free survival (hazard ratio [HR] 0·010, 95% CI 3·29 × 10 −4–0·0282; p=0·0067) and overall survival (0·080, 0·017–0·373; p=0·0012). The EPIMMUNE-positive signature was not associated with PD-L1 expression, the presence of CD8+ cells, or mutational load. EPIMMUNE-negative tumours were enriched in tumour-associated macrophages and neutrophils, cancer-associated fibroblasts, and senescent endothelial cells. The EPIMMUNE-positive signature was associated with improved progression-free survival in the EPIMMUNE validation cohort (0·330, 0·149–0·727; p=0·0064). The unmethylated status of FOXP1 was associated with improved progression-free survival (0·415, 0·209–0·802; p=0·0063) and overall survival (0·409, 0·220–0·780; p=0·0094) in the FOXP1 validation cohort. The EPIMMUNE signature and unmethylated FOXP1 were not associated with clinical benefit in lung tumours that did not receive immunotherapy. Interpretation: Our study shows that the epigenetic milieu of NSCLC tumours indicates which patients are most likely to benefit from nivolumab or pembrolizumab treatments. The methylation status of FOXP1 could be associated with validated predictive biomarkers such as PD-L1 staining and mutational load to better select patients who will experience clinical benefit with PD-1 blockade, and its predictive value should be evaluated in prospective studies.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

MeCP2-E1 isoform is a dynamically expressed, weakly DNA-bound protein with different protein and DNA interactions compared to MeCP2-E2

  • Martínez de Paz, Alexia
  • Khajavi, Leila
  • Martin, Hélène
  • Clavería Gimeno, Rafael
  • Dieck, Susanne Tom
  • Cheema, Manjinder
  • Sanchez-Mut, Jose Vicente
  • Moksa, Malgorzata M.
  • Carles, Annaick
  • Brodie, Nick I.
  • Sheikh, Taimoor I.
  • Freeman, Melissa E.
  • Petrotchenko, Evgeniy V.
  • Borchers, Christoph H.
  • Schuman, Erin M.
  • Zytnicki, Matthias
  • Velazquez-Campoy, Adrian
  • Abian, Olga
  • Hirst, Martin
  • Esteller, Manel
  • Vincent, John B.
  • Malnou, Cécile E.
  • Ausió, Juan
Background: MeCP2-a chromatin-binding protein associated with Rett syndrome-has two main isoforms, MeCP2-E1 and MeCP2-E2, differing in a few N-terminal amino acid residues. Previous studies have shown brain region-specific expression of these isoforms which, in addition to their different cellular localization and differential expression during brain development, suggest that they may also have non-overlapping molecular mechanisms. However, differential functions of MeCP2-E1 and E2 remain largely unexplored. Results: here, we show that the N-terminal domains (NTD) of MeCP2-E1 and E2 modulate the ability of the methyl-binding domain (MBD) to interact with DNA as well as influencing the turn-over rates, binding dynamics, response to neuronal depolarization, and circadian oscillations of the two isoforms. Our proteomics data indicate that both isoforms exhibit unique interacting protein partners. Moreover, genome-wide analysis using ChIP-seq provide evidence for a shared as well as a specific regulation of different sets of genes. Conclusions: our study supports the idea that Rett syndrome might arise from simultaneous impairment of cellular processes involving non-overlapping functions of MECP2 isoforms. For instance, MeCP2-E1 mutations might impact stimuli-dependent chromatin regulation, while MeCP2-E2 mutations could result in aberrant ribosomal expression. Overall, our findings provide insight into the functional complexity of MeCP2 by dissecting differential aspects of its two isoforms.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Precision medicine based in epigenomics: the paradigm of carcinoma of unknown primary

  • Moran, Sebastian
  • Martínez Cardús, Anna
  • Boussios, S.
  • Esteller, Manel
Epigenetic alterations are a common hallmark of human cancer. Single epigenetic markers are starting to be incorporated into clinical practice; however, the translational use of these biomarkers has not been validated at the 'omics' level. The identification of the tissue of origin in patients with cancer of unknown primary (CUP) is an example of how epigenomics can be incorporated in clinical settings, addressing an unmet need in the diagnostic and clinical management of these patients. Despite the great diagnostic advances made in the past decade, the use of traditional diagnostic procedures only enables the tissue of origin to be determined in ∼30% of patients with CUP. Thus, development of molecularly guided diagnostic strategies has emerged to complement traditional procedures, thereby improving the clinical management of patients with CUP. In this Review, we present the latest data on strategies using epigenetics and other molecular biomarkers to guide therapeutic decisions involving patients with CUP, and we highlight areas warranting further research to engage the medical community in this unmet need.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Circular RNA CpG island hypermethylation-associated silencing in human cancer

  • Ferreira, Humberto J.
  • Davalos, Veronica
  • Castro de Moura, Manuel
  • Soler, Marta
  • Pérez Salvia, Montserrat
  • Bueno Costa, Alberto
  • Setién, Fernando
  • Moran, Sebastian
  • Villanueva Garatachea, Alberto
  • Esteller, Manel
Noncoding RNAs (ncRNAs), such as microRNAs and long noncoding RNAs (lncRNAs), participate in cellular transformation. Work done in the last decade has also demonstrated that ncRNAs with growth-inhibitory functions can undergo promoter CpG island hypermethylation-associated silencing in tumorigenesis. Herein, we wondered whether circular RNAs (circRNAs), a type of RNA transcripts lacking 5′-3′ ends and forming closed loops that are gaining relevance in cancer biology, are also a target of epigenetic inactivation in tumors. To tackle this issue, we have used cancer cells genetically deficient for the DNA methyltransferase enzymes in conjuction with circRNA expression microarrays. We have found that the loss of DNA methylation provokes a release of circRNA silencing. In particular, we have identified that promoter CpG island hypermethylation of the genes TUSC3 (tumor suppressor candidate 3), POMT1 (protein O-mannosyltransferase 1), ATRNL1 (attractin-like 1) and SAMD4A (sterile alpha motif domain containing 4A) is linked to the transcriptional downregulation of both linear mRNA and the hosted circRNA. Although some circRNAs regulate the linear transcript, we did not observe changes in TUSC3 mRNA levels upon TUSC3 circ104557 overexpression. Interestingly, we found circRNA-mediated regulation of target miRNAs and an in vivo growth inhibitory effect upon TUSC3 circ104557 transduction. Data mining for 5′-end CpG island methylation of TUSC3, ATRNL1, POMT1 and SAMD4A in cancer cell lines and primary tumors showed that the epigenetic defect was commonly observed among different tumor types in association with the diminished expression of the corresponding transcript. Our findings support a role for circRNA DNA methylation-associated loss in human cancer.